Batavia adding 50 jobs in US viral vector and EU cleanroom expansion

By Dan Stanton contact

- Last updated on GMT

Related tags: Viral vector, Dna, Us

Batavia Biosciences will expand a Dutch production facility and build a viral vector plant in the US to cater for demand for its bioprocessing services.

The mammalian cell line generation and bioprocess development firm is adding 3,500 sq ft of lab and cleanroom space across the expansions at its GMP site in Leiden, The Netherlands, and at its R&D facility in Cambridge, Massachusetts.

Batavia Biosciences did not divulge the size of the investment but said the expansions were driven by an increase in general demand for its range of bioprocessing services.

These include “developing production and purification processes for vaccines, viral vectors, antibodies and proteins from the earliest product idea via full development to manufacturing of clinical material,”​ commercial director Vincent Franssen told Biopharma-Reporter.

“With the increased number of projects, the GMP extension fills in the increased need for the production of cell banks, master virus seeds, drug substance and drug product. At the same time, more projects demand more lab space, which is now covered with the creation of a new dedicated viral vector facility in the US. ”

He added the expansions will increase headcount by 50 across the two sites.

Viral vectors

The Cambridge expansion will bolster Batavia’s offering to include complete pre-clinical process development capabilities for viral vectors including AAV, Lentivirus, VSV and Adenovirus systems to its portfolio of CHO cell line generation and process development for recombinant proteins and antibodies.

Franssen said Batavia “is continuously attracting new projects and customers” ​due to its experience in viral vector projects and the growing interest in such products across the biopharma space.

“With the popularity of adenovirus, lentivirus, and AAV for vector vaccines and gene therapy products the demand for Batavia Biosciences’ viral vector work is rapidly increasing.”

Among the projects the firm is involved in is an attempt to produce an affordable rotavirus vaccine through an $8m grant from the Bill and Melinda Gates Foundation.

The programme is based on the RV3-BB rotavirus strain​​, a naturally occurring attenuated strain developed by the Murdoch Children’s Research Institute, and incorporating fixed-bed, high cell density single-use bioreactors instead of more traditional and expensive vessels. Bio Farm, an Indonesia state-owned vaccine producer and distributor, is charged with manufacturing the vaccine itself.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars